Inactive Instrument

Other languages Fennec Pharmaceuticals Inc Other OTC

Equities

CA31447P1009

Real-time Estimate Cboe BZX Other stock markets 01:05:10 2024-04-29 pm EDT			5-day change	1st Jan Change
9.2 ^USD	+29.94%		+3.66%	+10.97%

Apr. 23	Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	MT
Apr. 19	Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	Apr. 23
Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	Apr. 19
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing	Apr. 17
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing	Apr. 05
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing	Apr. 03
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share	Mar. 21
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21
Sector Update: Health Care Stocks Steady Premarket Monday	Mar. 18
Sector Update: Health Care	Mar. 18
Fennec Pharmaceuticals Inc. and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand	Mar. 17
Fennec Pharmaceuticals Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023	Feb. 29
Wedbush Reviews Fennec Pharmaceuticals' Q3 Results	Nov. 06
Fennec Pharmaceuticals Reports Pedmark Net Product Revenue of US$6.5 Million In Q3 2023	Nov. 06
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 06
Wedbush Reviews Fennec Pharmaceuticals' Q2	23-08-03
Fennec Pharmaceuticals Reports Q2 2023 Net Loss of US$5.4 Million; Appoints Adrian Haigh as Chief Operating Officer	23-08-03
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-03
Fennec Pharmaceuticals Inc. Announces the Appointment of Adrian Haigh as Chief Operating Officer	23-08-03
Insider Sell: Fennec Pharmaceuticals	23-06-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Fennec Pharmaceuticals Inc Other OTC

Equities

CA31447P1009

Other languages

Filters